440 related articles for article (PubMed ID: 38008609)
21. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
22. Steatotic liver disease, MASLD and risk of chronic kidney disease.
Bilson J; Mantovani A; Byrne CD; Targher G
Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
[TBL] [Abstract][Full Text] [Related]
23. Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study.
Jung YM; Lee SM; Wi W; Oh MJ; Park JS; Cho GJ; Kim W
JHEP Rep; 2024 Apr; 6(4):101033. PubMed ID: 38524668
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
[TBL] [Abstract][Full Text] [Related]
26. Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies.
Yasin A; Nguyen M; Sidhu A; Majety P; Spitz J; Asgharpour A; Siddiqui MS; Sperling LS; Quyyumi AA; Mehta A
Diabetes Res Clin Pract; 2024 May; 211():111650. PubMed ID: 38604447
[TBL] [Abstract][Full Text] [Related]
27. Fatty Liver Disease: Enter the Metabolic Era.
Wegermann K; Moylan C; Naggie S
Curr HIV/AIDS Rep; 2023 Dec; 20(6):405-418. PubMed ID: 37882965
[TBL] [Abstract][Full Text] [Related]
28. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
[TBL] [Abstract][Full Text] [Related]
29. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
30. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
Jiang Y; Wu L; Zhu X; Bian H; Gao X; Xia M
Lipids Health Dis; 2024 Apr; 23(1):95. PubMed ID: 38566209
[TBL] [Abstract][Full Text] [Related]
31. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
Stefan N; Hartleb M; Popovic B; Varona R
Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
[TBL] [Abstract][Full Text] [Related]
32. Update in lean metabolic dysfunction-associated steatotic liver disease.
Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
[TBL] [Abstract][Full Text] [Related]
33. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
Boldys A; Buldak L
World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
Zeng J; Fan JG; Francque SM
United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
[TBL] [Abstract][Full Text] [Related]
35. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
36. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
Hachuła M; Kosowski M; Basiak M; Okopień B
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37764998
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA
Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890
[TBL] [Abstract][Full Text] [Related]
38. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch M; Roden M; Kahl S
Metabolism; 2024 May; ():155937. PubMed ID: 38782182
[TBL] [Abstract][Full Text] [Related]
39. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
40. Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk.
Westcott F; Dearlove DJ; Hodson L
Atherosclerosis; 2024 Jul; 394():117237. PubMed ID: 37633797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
